** Shares of medical equipment maker Revvity RVTY.N fall 2.4% to $123.75

** Co forecast 2025 profit and revenue below estimates

** Co forecast 2025 adj. profit to be in the range of $4.90 to $5.00 per share, compared with analysts' estimates of $4.99, as per data compiled by LSEG

** Forecast 2025 revenue to be in the range of $2.80 bln to $2.85 bln, lower than estimates of $2.87 bln

** RVTY was expected to forecast lower with both Danaher DHR.N and Thermo Fisher TMO.N guiding lower vs. the Street expectations, brokerage Leerink Partners says

** Adds, "thus we see limited downside surprise" as the outlook is still 4% organic growth at the midpoint, which is higher vs. peers so far

** Co, however, beats Q4 profit and revenue estimates on strong sales in its life sciences and diagnostics units

** Reports Q4 adj. profit of $1.42 per share vs estimates of $1.37 per share

** Stock had risen 2.1% in 2024

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))